BRPI0821266A2 - Derivados de arilamida triazol-substituída e seu uso como anatagonistas de receptores purinérgicos p2x3 e/ou p2x2/3 - Google Patents

Derivados de arilamida triazol-substituída e seu uso como anatagonistas de receptores purinérgicos p2x3 e/ou p2x2/3

Info

Publication number: BRPI0821266A2
Authority: BR; Brazil
Prior art keywords: triazol; purinergic receptor; arylamide derivatives; substituted arylamide; receptor anatagonists
Prior art date: 2007-12-17

Application number

BRPI0821266-0A

Other languages

English (en)

Inventor

Li Chen

Michael Patrick Dillon

Lichun Feng

Ronald Charles Hawley

Minmin Yang

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-17

Filing date

2008-12-08

Publication date

2015-06-16

2008-12-08 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2008-12-08 Priority to BR122018070508A priority Critical patent/BR122018070508B8/pt

2015-06-16 Publication of BRPI0821266A2 publication Critical patent/BRPI0821266A2/pt

2019-01-29 Publication of BRPI0821266B1 publication Critical patent/BRPI0821266B1/pt

2023-02-07 Publication of BRPI0821266B8 publication Critical patent/BRPI0821266B8/pt

Links

102100037601 P2X purinoceptor 4 Human genes 0.000 title 1
108010080192 Purinergic Receptors Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Toxicology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Transplantation (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

BRPI0821266A 2007-12-17 2008-12-08 Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica BRPI0821266B8 (pt)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
BR122018070508A BR122018070508B8 (pt)	2007-12-17	2008-12-08	derivados de arilamida triazol-substituída e seu uso

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US789007P	2007-12-17	2007-12-17
PCT/EP2008/066987 WO2009077366A1 (en)	2007-12-17	2008-12-08	Triazole-substituted arylamide derivatives and their use as p2x3 and /or p2x2/3 purinergic receptor antagonists

Publications (3)

Publication Number	Publication Date
BRPI0821266A2 true BRPI0821266A2 (pt)	2015-06-16
BRPI0821266B1 BRPI0821266B1 (pt)	2019-01-29
BRPI0821266B8 BRPI0821266B8 (pt)	2023-02-07

Family

ID=40383852

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
BRPI0821266A BRPI0821266B8 (pt)	2007-12-17	2008-12-08	Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica
BR122018070508A BR122018070508B8 (pt)	2007-12-17	2008-12-08	derivados de arilamida triazol-substituída e seu uso

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
BR122018070508A BR122018070508B8 (pt)	2007-12-17	2008-12-08	derivados de arilamida triazol-substituída e seu uso

Country Status (12)

Country	Link
US (3)	US7989637B2 (pt)
EP (2)	EP2225213B1 (pt)
JP (2)	JP5318883B2 (pt)
KR (2)	KR101405746B1 (pt)
CN (1)	CN101903359B (pt)
AU (1)	AU2008337660B2 (pt)
BR (2)	BRPI0821266B8 (pt)
CA (1)	CA2707422C (pt)
ES (2)	ES2542245T3 (pt)
IL (1)	IL205608A (pt)
MX (1)	MX2010006230A (pt)
WO (1)	WO2009077366A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2234989B1 (en) *	2007-12-17	2014-08-13	F. Hoffmann-La Roche AG	Tetrazole-substituted arylamide derivatives and their use as p2x3 and/or p2x2/3 purinergic receptor antagonists
ES2542245T3 (es) *	2007-12-17	2015-08-03	F. Hoffmann-La Roche Ag	Derivados de arilamida sustituido con triazol y su utilización como antagonistas del receptor purinérgico P2x3 y/o P2x2/3
MX2010009561A (es)	2008-02-29	2010-09-24	Renovis Inc	Compuestos amida, composiciones y usos de los mismos.
CA2737038A1 (en)	2008-09-18	2010-03-25	Evotec Ag	Amide compounds, compositions and uses thereof
CN102574778B (zh)	2009-06-22	2015-01-07	弗·哈夫曼-拉罗切有限公司	新的联苯基和苯基-吡啶酰胺类化合物
EP2445889B1 (en) *	2009-06-22	2016-08-10	F.Hoffmann-La Roche Ag	Novel benzoxazolone -substituted arylamides
US10183937B2 (en)	2014-12-09	2019-01-22	Bayer Aktiengesellschaft	1,3-thiazol-2-yl substituted benzamides
HUE058009T2 (hu)	2014-12-09	2022-06-28	Bayer Ag	1,3-Tiazol-2-il szubsztituált benzamid-származékok
CN107207449B (zh)	2015-04-23	2020-11-10	豪夫迈·罗氏有限公司	用于治疗精神障碍的四唑衍生物
CN108137566B (zh) *	2015-10-06	2021-05-25	豪夫迈·罗氏有限公司	三唑衍生物
EP3411365B1 (en)	2016-02-02	2019-11-20	H. Hoffnabb-La Roche Ag	Pyrazol-pyridine derivatives as eaat3 inhibitors
TWI696615B (zh) *	2016-05-05	2020-06-21	瑞士商伊蘭科動物健康公司	雜芳基-1,2,4-三唑及雜芳基-三唑化合物
EP3464246B1 (en)	2016-05-27	2020-07-08	H. Hoffnabb-La Roche Ag	Pyrazol compounds as eaat3 inhibitors
CN109563049B (zh)	2016-10-14	2022-11-29	豪夫迈·罗氏有限公司	作为eaat3抑制剂的咪唑化合物
PY1986700A (es) *	2018-10-19	2020-08-28	Syngenta Participations Ag	Compuestos de azol-amida pesticidamente activos
WO2022068930A1 (zh) *	2020-09-30	2022-04-07	武汉人福创新药物研发中心有限公司	苯甲酰胺类化合物及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL109570A0 (en)	1993-05-17	1994-08-26	Fujisawa Pharmaceutical Co	Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
US6380187B2 (en)	1999-03-25	2002-04-30	Dingwei Tim Yu	Class of thiomorpholino substituted thiazoles
ES2250126T3 (es)	1999-06-30	2006-04-16	H. Lundbeck A/S	Antagonistas selectivos del npy(y5).
MY164523A (en)	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
KR20080021797A (ko)	2000-05-26	2008-03-07	이데닉스(케이만)리미티드	플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
AU2001268711A1 (en)	2000-06-23	2002-01-08	Bristol-Myers Squibb Pharma Company	Heteroaryl-phenyl substituted factor xa inhibitors
DE10055713A1 (de)	2000-11-10	2002-05-23	Dingwei Tim Yu	Neue Klasse von Antifungimitteln
WO2002057425A2 (en)	2001-01-22	2002-07-25	Merck & Co., Inc.	Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
NZ533107A (en)	2001-11-08	2007-04-27	Upjohn Co	N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
WO2003063791A2 (en)	2002-01-30	2003-08-07	Entremed, Inc.	Non-steroidal analogs of 2-methoxyestradiol
WO2003105770A2 (en)	2002-06-17	2003-12-24	Merck & Co., Inc.	Carbocyclic nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
BR0312271A (pt)	2002-06-28	2007-11-06	Idenix Cayman Ltd	compostos, composições e seus usos para o tratamento de infecções por flaviviridae
JP2005533852A (ja)	2002-07-18	2005-11-10	セレテックエルエルシー	Ｅｄｇ−１受容体に関連した症状の治療方法
HUE033832T2 (en)	2002-11-15	2018-01-29	Idenix Pharmaceuticals Llc	2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
TWI332507B (en)	2002-11-19	2010-11-01	Hoffmann La Roche	Antiviral nucleoside derivatives
US20070043512A1 (en)	2003-03-26	2007-02-22	Michael Rolph	Therapeutic and prophylactic compositions and uses therefor
EP1618099A4 (en)	2003-04-18	2008-07-16	Merck & Co Inc	BIARYLSUBSTITUTED DIAZOLE, OXAZOLE AND IMIDAZOLE AS SODIUM CHANNEL BLOCKERS
MXPA05012086A (es)	2003-05-12	2006-02-22	Pfizer Prod Inc	Inhibidores de benzamida del receptor p2x7.
WO2005020885A2 (en)	2003-05-21	2005-03-10	Isis Pharmaceuticals, Inc.	Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
EP1658302B1 (en)	2003-07-25	2010-08-25	IDENIX Pharmaceuticals, Inc.	Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
CN102659774A (zh) *	2005-08-15	2012-09-12	弗·哈夫曼-拉罗切有限公司	作为p2x3拮抗剂的哌啶和哌嗪衍生物
EP2592070B1 (en) *	2006-06-29	2016-08-31	F. Hoffmann-La Roche AG	Tetrazole-substituted arylamides
EP2091927B1 (en)	2006-11-09	2011-07-20	F. Hoffmann-La Roche AG	Thiazole and oxazole-substituted arylamides
CA2703909A1 (en) *	2007-10-31	2009-05-07	Merck Sharp & Dohme Corp.	P2x3, receptor antagonists for treatment of pain
ES2542245T3 (es) *	2007-12-17	2015-08-03	F. Hoffmann-La Roche Ag	Derivados de arilamida sustituido con triazol y su utilización como antagonistas del receptor purinérgico P2x3 y/o P2x2/3

2008
- 2008-12-08 ES ES12195604.9T patent/ES2542245T3/es active Active
- 2008-12-08 AU AU2008337660A patent/AU2008337660B2/en not_active Ceased
- 2008-12-08 EP EP20080861017 patent/EP2225213B1/en active Active
- 2008-12-08 CN CN2008801209500A patent/CN101903359B/zh active Active
- 2008-12-08 BR BRPI0821266A patent/BRPI0821266B8/pt active IP Right Grant
- 2008-12-08 BR BR122018070508A patent/BR122018070508B8/pt active IP Right Grant
- 2008-12-08 EP EP20120195604 patent/EP2607356B1/en active Active
- 2008-12-08 KR KR1020137005619A patent/KR101405746B1/ko active Active
- 2008-12-08 CA CA2707422A patent/CA2707422C/en active Active
- 2008-12-08 MX MX2010006230A patent/MX2010006230A/es active IP Right Grant
- 2008-12-08 KR KR1020107013245A patent/KR101284510B1/ko active Active
- 2008-12-08 WO PCT/EP2008/066987 patent/WO2009077366A1/en not_active Ceased
- 2008-12-08 ES ES08861017.5T patent/ES2541662T3/es active Active
- 2008-12-08 JP JP2010538559A patent/JP5318883B2/ja active Active
- 2008-12-17 US US12/317,017 patent/US7989637B2/en active Active - Reinstated
2010
- 2010-05-06 IL IL205608A patent/IL205608A/en not_active IP Right Cessation
2011
- 2011-06-16 US US13/162,378 patent/US8440708B2/en active Active
2013
- 2013-04-18 US US13/865,781 patent/US20150065521A1/en not_active Abandoned
- 2013-07-10 JP JP2013144402A patent/JP5697722B2/ja active Active

Also Published As

Publication number	Publication date
CA2707422C (en)	2016-06-07
JP5697722B2 (ja)	2015-04-08
ES2541662T3 (es)	2015-07-23
KR20130042002A (ko)	2013-04-25
IL205608A (en)	2016-03-31
BR122018070508B8 (pt)	2021-07-27
BRPI0821266B1 (pt)	2019-01-29
US7989637B2 (en)	2011-08-02
US20150065521A1 (en)	2015-03-05
US20110245271A1 (en)	2011-10-06
JP2011506521A (ja)	2011-03-03
EP2225213A1 (en)	2010-09-08
US8440708B2 (en)	2013-05-14
AU2008337660A1 (en)	2009-06-25
IL205608A0 (en)	2010-11-30
WO2009077366A1 (en)	2009-06-25
ES2542245T3 (es)	2015-08-03
MX2010006230A (es)	2010-06-23
JP5318883B2 (ja)	2013-10-16
CN101903359B (zh)	2013-05-22
BR122018070508B1 (pt)	2019-04-24
US20090170874A1 (en)	2009-07-02
EP2607356B1 (en)	2015-04-29
EP2225213B1 (en)	2015-04-29
EP2607356A1 (en)	2013-06-26
KR101284510B1 (ko)	2013-07-23
CN101903359A (zh)	2010-12-01
CA2707422A1 (en)	2009-06-25
JP2013231062A (ja)	2013-11-14
KR101405746B1 (ko)	2014-06-10
AU2008337660B2 (en)	2014-02-06
KR20100083196A (ko)	2010-07-21
BRPI0821266B8 (pt)	2023-02-07

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-05-08	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2018-07-17	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2018-11-27	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2019-01-29	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/01/2019, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2023-02-07	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: REFERENTE A RPI 2629 DE 25/05/2021, QUANTO AO ITEM (54) TITULO.

Publication	Publication Date	Title
BRPI0821266A2 (pt)	2015-06-16	Derivados de arilamida triazol-substituída e seu uso como anatagonistas de receptores purinérgicos p2x3 e/ou p2x2/3
BRPI0820838A2 (pt)	2015-06-16	Derivados de arilamida substituidos por tetrazol e seu uso como antagonistas do receptor purinérgico p2x3 e/ou p2x2/3
BRPI0814963A2 (pt)	2015-02-03	Pró-fármacos de dipeptóides e seu uso
PT2012833E (pt)	2014-12-23	Derivados de dihidrotetrabenazina radiomarcados e sua utilização como agentes de diagnóstico por imagem
BRPI0815043A2 (pt)	2017-05-23	mcp-1 mutantes antagonistas de glicosaminoglicanos e métodos para o seu uso
BR112012024870A2 (pt)	2016-06-14	derivados de 4-aminopirimidina e seus antagonistas do receptor a2a de adenosina
BRPI0810523A2 (pt)	2014-10-21	Derivado heterocíclico de 5 membros e uso do mesmo para propósitos médicos.
PT1725540E (pt)	2012-11-29	Diaminopirimidinas como antagonistas de p2x3 e p2x2/3
PL2170959T3 (pl)	2014-03-31	Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
BRPI0814267A2 (pt)	2015-03-31	Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
BRPI1010621A2 (pt)	2016-06-21	derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
BRPI0716936A2 (pt)	2013-09-17	derivados de adenosina como antigonistas de receptor de a2a
ATE481409T1 (de)	2010-10-15	Thiazolopyramidin/pyridinharnstoffderivate als antagonisten am adenosin-a2b-rezeptor
BRPI0820819A2 (pt)	2015-06-16	Formulação de anticorpos
BRPI0813244A2 (pt)	2014-12-23	Compostos e seus usos 708
BRPI0819410A2 (pt)	2016-07-19	"dispositivo com múltiplas camadas para detecção de analitos"
BRPI0817685A2 (pt)	2015-04-07	Polissacarídeos com funcionalidade azetidínio e seus usos
BRPI0807667A2 (pt)	2014-06-10	Composição emulsificada de óleo-em-água
BRPI0819014A2 (pt)	2015-09-08	"descanso de braço"
BRPI0720866A2 (pt)	2014-03-04	Derivados de oxindol substituídos e seu uso como ligandos de receptor de vasopressina
BRPI0818690A2 (pt)	2015-04-14	Derivados de quinazolinediona, sua preparação e seus usos terapêuticos.
BRPI0818216A2 (pt)	2015-09-29	derivado de amina tendo atividade antagonista do receptor npy y5 e uso do mesmo
DK2238110T3 (da)	2012-02-20	5.6-bisaryl-2-pyridin-carboxamid-derivater, fremstilling heraf og terapeutisk anvendelse heraf som urotensin II-receptorantagonister
BRPI0915552A2 (pt)	2017-06-20	derivados de ciclosporina, seu uso e sua composição farmacêutica
BRPI0808798A2 (pt)	2014-10-07	Fenoxifenilamidinas 3,5-dissubstituídas e seu uso como fungicidas